Biblioteca Hospital 12 de Octubre
Vista normal Vista MARC Vista ISBD

SEOM guidelines for the management of Malignant Melanoma 2015. [guía clínica]

Por: Martín, J.A.L [Oncología Médica].
Colaborador(es): Servicio de Oncología Médica.
Tipo de material: materialTypeLabelArtículoEditor: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2015Descripción: 17(12):1030-5.Recursos en línea: Acceso libre Resumen: All melanoma patients must be confirmed histologically and resected according to Breslow. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon must be offered for patients with high-risk melanoma and in selected cases radiotherapy can be added. Metastatic melanoma treatment is guided by mutational BRAF status. BRAF wild type patients must receive anti-PD1 therapy and BRAF mutated patients BRAF/MEK inhibitors or anti-PD1 therapy. Up to 10 years follow up is recommended for melanoma patients with dermatologic examinations and physical exams.
Etiquetas de esta biblioteca: No hay etiquetas de esta biblioteca para este título. Ingresar para agregar etiquetas.
    valoración media: 0.0 (0 votos)
Tipo de ítem Ubicación actual Signatura Estado Fecha de vencimiento
Guía clínica Guía clínica PC17358 (Navegar estantería) Disponible

Formato Vancouver:
Berrocal A, Arance A, Espinosa E, Castaño AG, Cao MG, Larriba J et al. SEOM guidelines for the management of Malignant Melanoma 2015. Clin Transl Oncol. 2015 Dec;17(12):1030-5.

PMID: 26669314
PMC4689745

Contiene 25 referencias

All melanoma patients must be confirmed histologically and resected according to Breslow. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon must be offered for patients with high-risk melanoma and in selected cases radiotherapy can be added. Metastatic melanoma treatment is guided by mutational BRAF status. BRAF wild type patients must receive anti-PD1 therapy and BRAF mutated patients BRAF/MEK inhibitors or anti-PD1 therapy. Up to 10 years follow up is recommended for melanoma patients with dermatologic examinations and physical exams.

No hay comentarios para este ejemplar.

Ingresar a su cuenta para colocar un comentario.

Con tecnología Koha